Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Seamless Design, Randomized, Double-blind, Paralleled-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

NCT06531512 is registered in ClinicalTrials.gov with Oneness Biotech Co., Ltd. as lead sponsor.

NCT NCT06531512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06531512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Seamless Design, Randomized, Double-blind, Paralleled-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers
Lead sponsor
Oneness Biotech Co., Ltd.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
August 16, 2024
Completion date
August 31, 2026
Enrollment
120 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer